Clinical Trials Logo

Cholangitis clinical trials

View clinical trials related to Cholangitis.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05525520 Active, not recruiting - Pruritus Clinical Trials

Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

PACIFIC
Start date: October 6, 2022
Phase: Phase 2
Study type: Interventional

This phase 2 trial will evaluate the effects of EP547 in subjects with cholestatic pruritus due to Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis (PSC)

NCT ID: NCT05239468 Active, not recruiting - Clinical trials for Primary Biliary Cholangitis

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Start date: March 21, 2022
Phase: Phase 2
Study type: Interventional

Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (OCA) in participants with Primary Biliary Cholangitis (PBC).

NCT ID: NCT05133336 Active, not recruiting - Clinical trials for Primary Biliary Cholangitis

Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

EPICS-III
Start date: April 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Saroglitazar Magnesium 1 mg and 2 mg tablets for treatment of subjects with Primary Biliary Cholangitis (PBC)

NCT ID: NCT05104853 Active, not recruiting - Clinical trials for Primary Biliary Cholangitis

Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

Start date: January 25, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-104. The study consists of a 120 day primary study followed by a 20 month long-term safety and durability of response follow-up period.

NCT ID: NCT05014672 Active, not recruiting - Clinical trials for Primary Biliary Cholangitis

A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

TRANSFORM
Start date: February 14, 2022
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the effect of setanaxib on alkaline phosphatase (ALP) at Week 24 in participants with PBC and with elevated liver stiffness and intolerance or inadequate response to ursodeoxycholic acid (UDCA).

NCT ID: NCT04981756 Active, not recruiting - Clinical trials for Primary Sclerosing Cholangitis

PSC Clinical Epidemiology in China

Start date: April 7, 2021
Phase:
Study type: Observational

Primary sclerosing cholangitis (PSC) is a rare disease but is increasingly reported in China (mainly in the Chinese language). However, most of the PSC literatures reported from China are case reports, small case series, and review articles. Up to now, there is no information on the epidemiology and disease burden of PSC in China. This study would use EMR/HIS and research databases to investigate the epidemiology, cascade, and treatment pattern of PSC in China.

NCT ID: NCT04751188 Active, not recruiting - Clinical trials for Primary Biliary Cirrhosis

A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis

Start date: October 2, 2020
Phase: Phase 3
Study type: Interventional

Up to 40% of patients with PBC have an inadequate response to standard treatment with Ursodeoxycholic Acid (UDCA), those patients represent the group in need for additional therapies, having increased risk of disease progression and decreased survival free of liver transplantation. The main objective of the study is to evaluate safety and efficacy of bezafibrate plus ursodesoxicolic acid in patients with PBC and inadequate response to UDCA.

NCT ID: NCT04691674 Active, not recruiting - Clinical trials for Post-ERCP Acute Pancreatitis

Optimal Placement Duration of Pancreatic Duct Stent

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

A randomized controlled trial to determine the optimal placement duration of pancreatic duct stents (PDS) inserted during ERCP: 2 vs 4 weeks

NCT ID: NCT04612413 Active, not recruiting - Sepsis Clinical Trials

A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

Start date: November 30, 2020
Phase: Phase 2
Study type: Interventional

A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

NCT ID: NCT04595825 Active, not recruiting - Clinical trials for Primary Sclerosing Cholangitis

CM-101 in PSC Patients -The SPRING Study

Start date: October 1, 2020
Phase: Phase 2
Study type: Interventional

This study is designed to assess the safety, tolerability and activity of the anti-human CCL24 monoclonal antibody CM-101 in adult subjects with Primary Sclerosing Cholangitis (PSC). At least 68 subjects at approximately 50 sites will be randomized to receive either CM-101 at doses of 10 mg/kg or 20 mg/kg or matching placebo.